Vincere Biosciences

Vincere Biosciences Increase mitophagy. Conquer disease. By doing so, we aim to transform the lives of hundreds of millions of patients across the globe.

Vincere Biosciences is dedicated to conquering age-related diseases through the development of small molecule therapeutics empowered by a suite of computational tools alongside traditional biology and drug discovery expertise. Our innovative approach focuses on developing small molecules that enhance the removal of damaged mitochondria by modulating mitochondrial quality control mechanisms, such a

s mitophagy. With the potential to be groundbreaking, these small molecules could become the world's first-ever medicines capable of slowing down or even halting the progression of debilitating conditions like Parkinson's disease and other age-related diseases. We welcome you to follow our page and other social media platforms for more content about our company, our dedicated team, and the science that drives what we do.

Mitophagy can save your lungs.At Vincere Biosciences, we develop mitophagy-based therapies to fight Parkinson's disease....
07/07/2026

Mitophagy can save your lungs.
At Vincere Biosciences, we develop mitophagy-based therapies to fight Parkinson's disease. But new research shows that mitophagy is responsible for the health of more than just your neurons.

A recent study published in Nature Communications shows that enhancing mitophagy in alveolar stem cells:

→ Restores mitochondrial fitness
→ Prevents cell death
→ Drives lung regeneration in fibrosis and viral pneumonia

At the center of this is a pathway we know well: PINK1/Parkin/USP30. The same mechanism that operates in neurons also operates in AT2 cells - the lung's alveolar stem cells.

Same pathway. Different diseases. That is the principle at the heart of our work.
Check the graphic to learn more.

07/01/2026

Dr. Spring Behrouz from Vincere Biosciences and Dr. Afshin Beheshti from the Broad Institute and President of COVID-19 International Research Team discuss the impact of COVID-19 on mitochondria and how it affects various organs in the body.

06/30/2026

Dr. Laurie Sanders ( Duke University) presents her publication "A blood-based marker of mitochondrial DNA damage in Parkinson’s disease" published in Science Translational Medicine on 30 August, 2023.

The study discusses the development of a PCR-based assay (Mito DNADX) for quantifying mitochondrial DNA (mtDNA) damage in a scalable platform, finding elevated mtDNA damage in certain Parkinson's Disease (PD) patients and models.

06/23/2026

Dr. Spring Behrouz from Vincere Biosciences and Dr. Afshin Beheshti from KBR at NASA Ames Research Center discuss how space travel has potential to be used as a model of accelerated aging.

06/22/2026

Vincere Biosciences co-founder and CBO, Andy Lee, describes the company's driving force and evolution in becoming a leader in the fight to stop Parkinson's disease.

06/17/2026

Hear Kwadwo Adomako, Research Associate at Vincere Biosciences, describes how he became interested in science, what drew him into research, and what fascinates him about working on therapeutics for aging.

06/16/2026

What accelerates brain aging the most?
Some lifestyle factors do not just affect how you feel day to day - they may directly influence brain aging and long-term cognitive health.

Andy Lee asked Spring Behrouz to rank several factors linked to accelerated brain aging:

😴 Chronic sleep deprivation
🍔 Ultra-processed food
🛋️ Sedentary lifestyle
👥 Social isolation
🦠 Viral infections
😰 Chronic stress
🌫️ Air pollution

Which one would you rank as the biggest driver of brain aging?
Check out the video 👇

06/15/2026

Mitochondria Monday ⚡️

True or False? Mitochondria edition! Vincere Bio's Co-founder & CEO, Dr. Spring Behrouz answers true/false and discusses the topics:

• Mitochondria and disease

10 million people globally are living with Parkinson’s.And we’re still catching up on what’s really driving it.Genetic m...
06/14/2026

10 million people globally are living with Parkinson’s.
And we’re still catching up on what’s really driving it.

Genetic mutations that cause Parkinson’s have helped researchers uncover the cellular pathways behind the disease: pathways that we are now targeting with therapies designed to stop the disease, not just manage symptoms.

Check out some of the key pathways involved. 👇

06/13/2026

What is USP30?

At Vincere Biosciences, we are developing therapies designed to enhance mitophagy - the cell's natural process for removing damaged mitochondria - to help fight age-related diseases.

One of our key targets is USP30, a protein that acts as a brake on mitophagy.

Check out this short video, where Spring explains what USP30 is and why it matters.

Address

Boston, MA

Website

,

Alerts

Be the first to know and let us send you an email when Vincere Biosciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category